DK0655917T3 - Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme - Google Patents

Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme

Info

Publication number
DK0655917T3
DK0655917T3 DK93918552T DK93918552T DK0655917T3 DK 0655917 T3 DK0655917 T3 DK 0655917T3 DK 93918552 T DK93918552 T DK 93918552T DK 93918552 T DK93918552 T DK 93918552T DK 0655917 T3 DK0655917 T3 DK 0655917T3
Authority
DK
Denmark
Prior art keywords
preparations
present
crystalline
processes
preparation
Prior art date
Application number
DK93918552T
Other languages
Danish (da)
English (en)
Inventor
Paul E Kennedy
Roger A Rajewski
John M Baldoni
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26795942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0655917(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/099,298 external-priority patent/US5424471A/en
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Application granted granted Critical
Publication of DK0655917T3 publication Critical patent/DK0655917T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Organic Insulating Materials (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)
DK93918552T 1992-07-31 1993-07-30 Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme DK0655917T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92292992A 1992-07-31 1992-07-31
US08/099,298 US5424471A (en) 1992-07-31 1993-07-29 Crystalline amifostine compositions and methods of the preparation and use of same
PCT/US1993/007222 WO1994003179A1 (fr) 1992-07-31 1993-07-30 Compositions d'amifostine cristalline et leurs procedes de preparation et d'utilisation

Publications (1)

Publication Number Publication Date
DK0655917T3 true DK0655917T3 (da) 2004-07-26

Family

ID=26795942

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93918552T DK0655917T3 (da) 1992-07-31 1993-07-30 Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme

Country Status (23)

Country Link
US (1) US5591731A (fr)
EP (1) EP0655917B1 (fr)
JP (1) JP3503943B2 (fr)
CN (2) CN1070370C (fr)
AT (1) ATE261729T1 (fr)
AU (1) AU681858B2 (fr)
CA (1) CA2120133C (fr)
CZ (1) CZ284417B6 (fr)
DE (1) DE69333453T2 (fr)
DK (1) DK0655917T3 (fr)
ES (1) ES2215992T3 (fr)
HK (1) HK1010692A1 (fr)
HU (1) HU227122B1 (fr)
IL (1) IL106540A (fr)
IS (1) IS1843B (fr)
MX (1) MX9304627A (fr)
NO (2) NO309636B1 (fr)
NZ (1) NZ255182A (fr)
PL (1) PL178463B1 (fr)
PT (1) PT655917E (fr)
RU (1) RU2125880C1 (fr)
SG (1) SG47101A1 (fr)
SK (1) SK283318B6 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6407278B2 (en) 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
CN1148192C (zh) * 2000-10-19 2004-05-05 南京振中生物工程有限公司 细胞保护剂氨磷汀制剂及其制备方法
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
EP1490090A4 (fr) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
CN1305478C (zh) * 2004-05-12 2007-03-21 天津市资福医药科技开发有限公司 氨磷汀冻干制剂及其制备方法
HUE054365T2 (hu) 2005-02-16 2021-09-28 Anacor Pharmaceuticals Inc Bór-ftalidok terápiás alkalmazásra
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2007047315A1 (fr) * 2005-10-20 2007-04-26 Albemarle Corporation Composition cristalline de dihydrate d'amifostine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
DK2719388T3 (da) * 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
US9585849B2 (en) 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
US20090239817A1 (en) * 2006-04-17 2009-09-24 Goverment Of The United States Of America, As Represented By The Secretary, Dept Of Health Organic thiophosphate antiretroviral agents
US8815833B2 (en) * 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
ES2630036T3 (es) 2008-03-06 2017-08-17 Anacor Pharmaceuticals, Inc. Moléculas pequeñas que contienen boro como agentes antiinflamatorios
EP2285384A4 (fr) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
CN101412732B (zh) * 2008-09-02 2011-09-07 大连美罗药业股份有限公司 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (fr) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
WO2010045503A1 (fr) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu’agents antiprotozoaires
CN102256494A (zh) * 2008-12-17 2011-11-23 阿纳科制药公司 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
EP2458995A1 (fr) * 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Molécules contenant du bore trisubstitué
US9440994B2 (en) 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
WO2011022337A1 (fr) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents anti-protozoaires
WO2011037731A1 (fr) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) * 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
HUE037281T2 (hu) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
WO2011094450A1 (fr) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Petites molecules contenant du bore
WO2011116348A1 (fr) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Petites molécules borées en tant qu'agent anti-protozoaire
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ES2898695T3 (es) 2010-09-07 2022-03-08 Anacor Pharmaceuticals Inc Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
CN102286020A (zh) * 2011-07-11 2011-12-21 大连美罗大药厂 一水合3-氨基丙基胺乙基硫代磷酸的制备方法
MX370021B (es) 2013-03-15 2019-11-28 Tonix Pharmaceuticals Inc Formulaciones eutécticas de clorhidrato de ciclobenzaprina y de clorhidrato de amitriptilina.
CA2915708C (fr) * 2013-06-18 2018-02-06 Aminomedix Inc. Compositions et procedes utilisables en vue de la preparation d'agents protecteurs renaux contenant de l'amifostine et des acides amines
US10357465B2 (en) 2014-09-18 2019-07-23 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
WO2016054458A1 (fr) * 2014-10-02 2016-04-07 Cytosorbents Corporation Utilisation de polymères poreux sorbants entériques administrés par voie gastrointestinale pour prévenir ou traiter la mucosite, l'œsophagite, l'entérite, la colite, et le syndrome gastro-intestinal aigu d'irradiation induits par l'irradiation
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
MX2020006140A (es) 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
CN110616463B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备有机半导体分子单晶或无定型物的方法
CN110735176B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备配位化合物单晶或无定型物的方法
CN110606868A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备多肽或蛋白质单晶或无定型物的方法
CN110607555B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备紫杉醇单晶或无定型物的方法
CN110607551B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备食品添加剂单晶或无定型物的方法
WO2020088479A1 (fr) * 2018-10-30 2020-05-07 中国科学院化学研究所 Procédé d'utilisation d'une solution aqueuse pour préparer un monocristal ou une substance amorphe
CN110735177B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种利用溶液冻结制备单晶或无定型物的方法
EP3824880A1 (fr) * 2019-11-25 2021-05-26 Clevexel Pharma Poudre lyophilisée contenant du 2-[(3-aminopropyl)amino]éthanethiol et son utilisation pour la préparation d'un thermogel
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) * 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
WO1986001110A1 (fr) * 1984-08-08 1986-02-27 Survival Technology, Inc. Agents ameliorant l'absorption
JPH04505760A (ja) * 1989-05-24 1992-10-08 ユー・エス・バイオサイエンス Ａｚｔの副作用および毒性からの保護方法

Also Published As

Publication number Publication date
PL178463B1 (pl) 2000-05-31
AU681858B2 (en) 1997-09-11
SG47101A1 (en) 1998-03-20
PT655917E (pt) 2004-08-31
US5591731A (en) 1997-01-07
SK11395A3 (en) 1995-07-11
AU4796693A (en) 1994-03-03
IL106540A0 (en) 1994-08-26
EP0655917A4 (fr) 1995-08-02
NO20005775D0 (no) 2000-11-15
PL307298A1 (en) 1995-05-15
HU227122B1 (en) 2010-07-28
ES2215992T3 (es) 2004-10-16
HK1010692A1 (en) 1999-06-25
NO5775A (no) 1995-03-22
RU2125880C1 (ru) 1999-02-10
JPH08500104A (ja) 1996-01-09
CA2120133C (fr) 1998-06-09
CN1307870A (zh) 2001-08-15
NO315691B1 (no) 2003-10-13
CA2120133A1 (fr) 1994-02-17
CN1070370C (zh) 2001-09-05
MX9304627A (es) 1994-04-29
JP3503943B2 (ja) 2004-03-08
DE69333453T2 (de) 2005-01-27
CZ23095A3 (en) 1995-10-18
DE69333453D1 (de) 2004-04-22
CN1146428C (zh) 2004-04-21
NO309636B1 (no) 2001-03-05
EP0655917A1 (fr) 1995-06-07
ATE261729T1 (de) 2004-04-15
IL106540A (en) 2000-02-17
IS4060A (is) 1994-02-01
SK283318B6 (sk) 2003-05-02
NZ255182A (en) 1996-12-20
CZ284417B6 (cs) 1998-11-11
NO950343L (no) 1995-03-22
IS1843B (is) 2003-01-30
HUT70191A (en) 1995-09-28
NO950343D0 (no) 1995-01-30
CN1092980A (zh) 1994-10-05
EP0655917B1 (fr) 2004-03-17
HU9500277D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
DK0655917T3 (da) Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme
MY110631A (en) Crystalline amifostine compositions and methods for the preparation and use of same.
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
GB9930882D0 (en) GLP-2 formulations
NO173015C (no) Analogifremgangsmaate til fremstilling av pyrido(1,2-a)pyrimidin-3-piperidinyl-1,2-benzisoksazoler
DK0948527T3 (da) Cylosporinderivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
DK1206189T3 (da) Rotavirusvaccineformuleringer
WO2001005355A3 (fr) Formulations d'il-11
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
NO176840C (no) Analogifremgangsmåte for fremstilling av 2,9-disubstituerte-4H-pyrido[1,2-aÅpyrimidin-4-oner
HUP0100083A2 (hu) Piridingyűrűt tartalmazó kondenzált, tetraciklusos vegyületek, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
HUP0300389A2 (hu) A kabergolin II. kristályformája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
ZA979647B (en) Heterocyclic compounds, compositions and uses.
DK0536197T3 (da) Ren, krystallinsk form af rifapentine
NO985202D0 (no) Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
ZA979650B (en) Heterocyclic compounds, compositions and uses.
ZA979645B (en) Heterocyclic compounds, compositions and uses.
EP0382635A3 (fr) Utilisation de dérivés d'alkyl-5 pyridazine comme médicaments actifs sur le système cholinergique
ITMI912324A1 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche.
SE8700829L (sv) Farmaceutisk komposition